tiprankstipranks
Statera BioPharma (STAB)
OTHER OTC:STAB
US Market

Statera BioPharma (STAB) Income Statement

190 Followers

Statera BioPharma Income Statement

Last quarter (Q3 2022), Statera BioPharma's total revenue was $670.47K, an increase of Infinity% from the same quarter last year. In Q3, Statera BioPharma's net income was $-3.35M. See Statera BioPharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19
Total Revenue
$ 670.47K$ 1.49M$ 262.94K$ 0.00
Cost of Revenue
$ 895.41K$ 488.31K--
Gross Profit
$ -895.41K$ 998.72K$ 262.94K-
Operating Expense
$ 13.95M$ 99.34M$ 10.50M$ 2.81M
Operating Income
$ -17.44M$ -98.34M$ -10.50M$ -2.81M
Net Non Operating Interest Income Expense
$ -2.24M--$ -124.23K
Other Income Expense
$ -138.96K$ 3.53M$ 1.59M$ -285.61K
Pretax Income
$ -88.37M$ -101.88M$ -12.09M$ -3.22M
Tax Provision
----
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
$ -91.84M$ -101.85M$ -12.09M$ -3.22M
Basic EPS
$ -2.45$ -2.90$ -1.66$ -0.13
Diluted EPS
$ -2.45$ -2.90$ -1.66$ -0.13
Basic Average Shares
$ 123.97M$ 35.11M$ 7.30M$ 25.65M
Diluted Average Shares
$ 123.97M$ 35.11M$ 7.30M$ 25.65M
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
$ 18.19M$ 99.83M$ 10.50M$ 2.81M
Net Income From Continuing And Discontinued Operation
$ -91.84M$ -101.85M$ -12.09M$ -3.22M
Normalized Income
$ -87.43M$ -12.88M-$ -3.22M
Interest Expense
$ 1.15M--$ 124.23K
EBIT
$ -19.55M$ -101.88M$ -12.09M$ -2.81M
EBITDA
$ -19.00M$ -101.60M$ -12.09M$ -2.81M
Currency in USD

Statera BioPharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis